Quiz for Clinicians – Test Your Knowledge Around Obesity Management
Reviewed by: HU Medical Review Board | Last reviewed: July 2026 | Last updated: September 2026
Editor's Note: The Medicare GLP-1 Bridge is an evolving federal demonstration, currently authorized through December 31, 2027. The Part D portion of the successor BALANCE Model has been delayed and no replacement has been finalized. This information is subject to change based on upcoming CMS guidance and federal rulemaking.
Think you're up to speed on the fastest-moving areas of obesity care? This five-question quiz covers managing GLP-1 side effects, navigating the new Medicare GLP-1 Bridge coverage rules, and treating obesity in older adults.
Clinical Challenge
A patient with obesity is titrated to a higher maintenance dose of a GLP-1 or GLP-1/GIP receptor agonist and develops nausea and intermittent vomiting that make it hard to eat. She is tolerating fluids and has no severe abdominal pain, fever, or signs of obstruction. What is the most appropriate next step?
Clinical Challenge
The Medicare GLP-1 Bridge gives eligible Part D beneficiaries access to select incretin-based therapies for obesity at a fixed monthly copay. A patient with obesity (no diabetes) currently uses an injectable GLP-1 receptor agonist approved for type 2 diabetes and asks you to bill it through the Bridge for weight loss. What should you tell them?
Clinical Challenge
Which of the following Medicare Part D beneficiaries meets the clinical eligibility criteria to be attested for the Medicare GLP-1 Bridge?
Clinical Challenge
A 78-year-old with obesity (BMI 33) and early sarcopenia is started on an incretin-based therapy for weight management. Body-composition substudies of major trials show that a meaningful share of drug-induced weight loss – in some cases over a third – comes from lean tissue. Which concurrent intervention is most important to prevent further frailty and functional decline in this patient?
Clinical Challenge
Before initiating any GLP-1-based therapy for obesity – including the newer oral small-molecule agents – which patient history is an absolute, class-wide contraindication?